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AbstrAct
Introduction A functioning voice is essential for normal 
human communication. A good voice requires two moving 
vocal folds; if one fold is paralysed (unilateral vocal fold 
paralysis (UVFP)) people suffer from a breathy, weak 
voice that tires easily and is unable to function normally. 
UVFP can also result in choking and breathlessness. 
Current treatment for adults with UVFP is speech 
therapy to stimulate recovery of vocal fold (VF) motion 
or function and/or injection of the paralysed VF with a 
material to move it into a more favourable position for the 
functioning VF to close against. When these therapies are 
unsuccessful, or only provide temporary relief, surgery is 
offered. Two available surgical techniques are: (1) surgical 
medialisation; placing an implant near the paralysed VF to 
move it to the middle (thyroplasty) and/or repositioning the 
cartilage (arytenoid adduction) or (2) restoring the nerve 
supply to the VF (laryngeal reinnervation). Currently there 
is limited evidence to determine which surgery should be 
offered to adults with UVFP.
Methods and analysis A feasibility study to test the 
practicality of running a multicentre, randomised clinical 
trial of surgery for UVFP, including: (1) a qualitative 
study to understand the recruitment process and how it 
operates in clinical centres and (2) a small randomised 
trial of 30 participants recruited at 3 UK sites comparing 
non-selective laryngeal reinnervation to type I thyroplasty. 
Participants will be followed up for 12 months. The 
primary outcome focuses on recruitment and retention, 
with secondary outcomes covering voice, swallowing and 
quality of life.
Ethics and dissemination Ethical approval was 
received from National Research Ethics Service—
Committee Bromley (reference 11/LO/0583). In addition 
to dissemination of results through presentation and 
publication of peer-reviewed articles, results will be shared 
with key clinician and patient groups required to develop 
the future large-scale randomised controlled trial.
trial registration number ISRCTN90201732; 16 
December 2015.
IntroductIon
The larynx provides the main tool for human 
social interaction. The vocal folds are inner-
vated by the recurrent laryngeal nerve (RLN) 
and when this nerve supply to one vocal fold 
is interrupted, unilateral vocal fold paral-
ysis (UVFP) ensues. Patients suffering with 
UVFP typically display a weak, hoarse voice1 
that tires easily, with some also suffering 
from breathing and swallowing problems. 
Quality of life of these patients is significantly 
reduced, with UVFP affecting their ability 
to interact socially and perform job func-
tions.2 3Therefore, optimum restoration of 
the paralysed larynx is important for patients 
to lead full personal and professional lives.
The aim of treatment for UVFP is to 
achieve optimum vocal fold (VF) closure 
for voice production. Where speech therapy 
alone does not improve the voice suffi-
ciently, surgical treatment is undertaken. 
While short-term relief of symptoms can 
be achieved via injection of the paralysed 
VF with a material to improve its position 
for the functioning VF to close against it, 
permanent results are only possible by two 
types of operation: surgical medialisation 
and laryngeal reinnervation. One method of 
the former is to insert a synthetic implant to 
move the paralysed VF into a better position 
for speaking (type1 thyroplasty), while the 
latter resupplies nerves to improve muscle 
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bulk and tone (non-selective laryngeal reinnervation). 
Type I thyroplasty is a 1-hour operation under local anaes-
thetic where the medium grade silastic implant is inserted 
through a window in the cartilage lamina of the larynx. 
This implant medialises the paralysed VF in the midline 
position enabling the normal opposite vocal fold to make 
a firmer contact, producing a stronger voice. However, 
voice improvement may be short-term due to progressive 
atrophy of the denervated laryngeal muscles.4 Further-
more, this procedure does not restore vocal fold tension, 
meaning that pitch variation remains suboptimal.5 6 
Reports on short and long-term voice outcomes of patients 
with thyroplasty are sparse and methodologically poor.7 
The newer approach to restoring laryngeal function in 
UVFP patients, non-selective laryngeal reinnervation, is a 
2-hour operation under general anaesthesia in which the 
injured RLN and the donor nerve are identified and anas-
tomosed. Its aim is to restore innervation to the larynx by 
‘borrowing’ the activity of other motor nerves, specifically 
the ansa cervicalis. As such it may re-establish the tone 
and bulk of the vocal folds during speech and re-enable 
pitch control, resulting in normal or sufficient voice. The 
operation is safe and results in sustained improvement 
of glottal closure, maintenance of the vocal fold edge 
and significant improvements in voice quality have been 
reported.8
A systematic review of studies on laryngeal reinnerva-
tion revealed that the quality of current literature is low 
and a formal prospective trial was recommended using 
standardised, internationally accepted outcomes.9 Before 
embarking on a trial that will use public resources and the 
time of patients and healthcare staff, we need to confirm 
that running a trial is feasible and that the chosen 
outcome measures truly reflect voice quality and patients’ 
perceptions.10 11 For these reasons, and others given 
above, a feasibility study is critical prior to designing, with 
patients, a multicentre, phase III randomised clinical trial 
of treatment for this disabling condition.
MEthods And AnAlysIs
objectives
The primary research objective is to determine the feasi-
bility of performing a multicentre phase III randomised 
controlled trial (RCT) of laryngeal reinnervation versus 
type I thyroplasty for adult patients with UVFP.
The secondary research objectives are to test the feasi-
bility of:
1. The multicentre recruitment process, including 
continuous improvement to the process based on 
qualitative methodology;
2. Recruiters being able to present true equipoise with 
the treatment arms;
3. The randomisation processes and to investigate rea-
sons for any difficulties that affect recruitment;
4. The use of the following characteristics of the pro-
posed primary and secondary outcomes: variability 
across patients, variability over time, differences in 
outcome between randomised groups over time;
5. Process of follow-up visits;
6. Means of gathering health economics and health-
related quality of life data suitable for measuring cost-
effectiveness.
study design
The feasibility study will consist of two research approaches 
run in parallel:
1. Qualitative: the Quintet Recruitment Intervention 
(QRI) to understand the recruitment process and 
how it operates in clinical centres, so that sources 
of recruitment difficulties can be identified and 
suggestions made to change aspects of design, 
conduct, organisation or training that could then lead 
to improvements in recruitment12;
2. Quantitative: a small randomised surgical trial of 
30 patients to compare non-selective laryngeal 
reinnervation to type I thyroplasty. Patients will be 
randomised in a 1:1 ratio.
The study is single blinded whereby the raters of the 
secondary quantitative outcome of acoustic measures 
will be blinded to the time-point of the data record-
ings (preoperative or postoperative) and blinded to 
strengths and limitations of this study
 ► This is the first clinical trial to be run in the UK to compare the 
effectiveness of two surgical approaches for restoration of laryngeal 
function in adults with unilateral vocal fold paralysis (UVFP).
 ► This study has been developed in response to: (1) patient demand 
and (2) a systematic review that reported a low quality of current 
literature available on laryngeal reinnervation and proposed 
that a formal prospective trial was required using standardised, 
internationally accepted outcomes.
 ► A similar trial, comparing laryngeal reinnervation and type I 
thyroplasty in adults with UVFP, was previously run in the USA, but 
was suspended prematurely due to irregularity in obtaining inform 
consent and low accrual. We acknowledge the challenges associated 
with recruiting to a phase III surgical study of this type and have 
sought to overcome them by: (1) learning from this previous trial; 
(2) designing this rigorous feasibility study to be conducted prior to 
running a larger scale phase III randomised controlled trial and (3) 
involving patients with UVFP throughout the feasibility study design, 
set up, analysis and dissemination processes.
 ► Our research team is multidisciplinary and our study design 
incorporates both qualitative and quantitative components.
 ► While our study focuses on voice-related criteria for inclusion, our 
design includes outcomes relating to both the voice and swallowing.
 ► Although participants and study personnel are not blinded 
to their allocated treatment group, the speech therapist and 
neurophysiologist outcome raters are blinded.
 ► Very few ear, nose and throat surgeons in the UK are trained to 
perform laryngeal reinnervation and so our study is limited to 
recruiting at those relevant UK sites.
 ► While we aim to follow-up all participants for 12 months, budget and 
time constraints may limit some of the latterly recruited participant 
follow-up to 6 months. However, all patients are followed up 
clinically in the long term.
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surgical intervention (laryngeal reinnervation or type I 
thyroplasty).
Participants
Inclusion criteria
1. UVFP due to unilateral recurrent laryngeal nerve 
paralysis of traumatic, iatrogenic or idiopathic origin 
of between 6 and 60 months duration or symptoms 
that have not sufficiently improved with speech 
therapy alone, as determined by the patient and 
agreed by a multidisciplinary clinical team, after 6 
months and pending a surgical decision;
2. Age from 18 to 70 years old;
3. Male or female;
4. Able to provide informed consent;
5. A significant voice disorder as measured by perceptu-
al rating (GRBAS (grade, roughness, breathiness, as-
thenia, strain) Grade≥2)13 and Voice Handicap Index 
(VHI-10 score >16)14;
6. Common laryngeal electromyography (LEMG, 
neurophysiological) criteria (Koufman Grades 
2–5)15 in either the thyroarytenoid or posterior 
cricoarytenoid muscle on the paralysed side.
Exclusion criteria
1. Impaired vocal fold mobility but a normal EMG 
(Koufman Grade I);
2. Severe lung disorders;
3. Structural vocal fold lesions such as polyp;
4. Previous laryngeal framework surgery;
5. Cricoarytenoid joint fixation;
6. Significant non-laryngeal speech abnormality (severe 
dysarthria determined by a panel of trained speech 
therapists);
7. Previous level 2, 3 or 4 thyroid neck dissection;
8. Previous ipsilateral surgical neck dissection;
9. Previous radiotherapy to the head and neck;
10. Laryngeal injection of a rapidly absorbable material 
in the last 6 months;
11. Previous laryngeal injection of a non-rapidly 
absorbable material (eg, bioplastics, voice examiner);
12. Neuromuscular disease affecting the larynx or 
multiple cranial nerve palsies.
setting
The study is sponsored by University College London 
Hospitals National Health Service (NHS) Foundation 
Trust. Potential participants will be recruited from three 
UK hospitals; the Royal National Throat, Nose and Ear 
Hospital (University College London Hospitals NHS 
Foundation Trust), Manchester Royal Infirmary (Central 
Manchester University Hospitals NHS Foundation Trust) 
and Poole Hospital (Poole Hospital NHS Foundation 
Trust). The study is run through the University College 
London evidENT team, with qualitative data analysed by 
the University of Bristol and quantitative data analysed 
by University College London and Australian Catholic 
University.
Interventions
Laryngeal reinnervation: the surgical technique is an 
unselective reinnervation16 that aims to improve the 
muscle tone and bulk. Performed under general anaes-
thesia, the injured RLN and the donor nerve are identi-
fied and anastomosed.
Type 1 thyroplasty: this medialisation/augmentation 
technique is a static technique,17 performed under local 
anaesthesia that aims to improve the positioning of the 
paralysed vocal fold. It uses a medium grade silastic 
implant, cut by the surgeon into the correct size for 
the patient. This size is determined intraoperatively by 
using a measuring device while listening and visualising 
the larynx with flexible fibreoptic scope simultaneously. 
Concurrent arytenoid adduction is permitted to be 
performed in cases where there is a significant posterior 
gap that cannot be approximated with the silicon block 
alone.
outcome measures
The primary outcomes are from those patients who were 
eligible to enter the study:
1. Whether the patient was randomised (yes/no);
2. Whether the participant successfully received the allo-
cated operation (yes/no);
3. Whether the participant completed the trial (yes/no).
The quantitative secondary outcomes are:
1. General health status measured using the validated 
EuroQoL 5 Dimensions 5 Levels18 questionnaire. 
Participants will self-administer the questionnaires at 
baseline, 6 and 12 months.
2. Voice-related quality of life measured using the 
validated VHI-10.14 Participants will self-administer 
the questionnaires at baseline, 6 and 12 months.
3. Swallowing-related quality of life measured using 
the validated Eating Assessment Tool (EAT-10.19 
Participants will self-administer the questionnaires at 
baseline, 6 and 12 months.
4. Vocal fold vibration measured detected using 
laryngeal videostroboscopy and graded using the 
Stroboscopy Research Instrument scale.20 Data will be 
collected at baseline, 6 and 12 months, anonymised 
and analysed by three independent trained raters.
5. Perceptual voice quality measured using the GRBAS13 
four-point grading scale (0—normal or absence 
of deviance; 1—slight deviance; 2—moderate 
deviance and 3—severe deviance) to evaluate ‘G’; 
the grade of the overall voice quality, ‘R’; roughness 
or harshness, ‘B’; breathiness, ‘A’; asthenia and ‘S’; 
strain. Voice recordings will be collected at baseline, 
6 months and 12 months, anonymised and graded 
by three independent experienced speech therapists 
trained to enhance the intra-rater and inter-rater 
agreement.21
6. Acoustic voice quality of the participants’ voice 
recording will be captured and measured using the 
‘On person Rapid Voice Examiner’,22 a specially 
designed portable voice analysis application that 
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will be loaded onto Apple iPod Touch devices at 
each recruitment site. The noise-to-harmonic ratio, 
harmonic-to-noise, jitter, shimmer, shimmer dB, 
fundamental frequency, pitch range and maximum 
phonation time (MPT) data will be collected at 
baseline, 6 months and 12 months.
7. Swallow volume, capacity and speed measured using 
the validated 100 mL water Swallow Test20 at baseline, 
6 months and 12 months.
8. Laryngeal muscle activity detected using LEMG and 
graded using the Koufman grading scale.15 Data 
obtained will be collected at baseline and 12 months, 
anonymised and analysed by three independent 
neurophysiologists.
9. Health economic cost analysis of laryngeal 
reinnervation and thyroplasty procedures including 
the costs of the index procedure (staff costs, theatre 
costs, costs of consumables, recovery costs).
10. Feasibility assessment of conducting a full economic 
evaluation of laryngeal reinnervation versus 
thyroplasty alongside the future large-scale RCT. 
Data will be collected to identify: (1) the main NHS/
Personal Social Services cost components; (2) the 
main costs borne by patients and families and (3) the 
resource use and unit cost data required for each of 
these cost components and how best to source these.
The qualitative secondary outcomes are:
1. Whether members of the Study Management Group 
(SMG) and recruiters are in equipoise with the 
treatment arms;
2. Patient views and beliefs on randomisation, recruit-
ment and retention processes;
3. Patient and surgeon/speech therapist views on cho-
sen outcome measures;
4. Recruiter–patient interactions.
sample size
The sample size of 30 participants (15 per arm) will allow 
us to demonstrate the feasibility of conducting a full-scale 
randomised trial in the future. This study is not formally 
powered to detect differences (although we note that 
the sample would be able to detect very large effects, 
for example, a standardised effect of 1 with approxi-
mately 80% power). Rather, the sample size was based on 
Julious20 who suggests a group size of at least 12 to obtain 
reasonably precise estimates of an effect and its variance.
Participant flow
During the 15-month recruitment period, potential partic-
ipants will attend an initial ear, nose and throat (ENT 
consultation with the local principal investigator (PI). If 
they are deemed a potential candidate for the study, the 
PI will ask the patient for verbal consent to audiorecord 
subsequent conversations where information about the 
VOCALIST study is given. The PI will then provide the 
participant information sheet (PIS). After the consulta-
tion, the local research nurse (RN) will go through the 
PIS with the patient and answer any questions the patient 
may have. This conversation will also be audiorecorded 
and during this conversation the RN will ask the patient 
to complete written informed preconsent for the conver-
sations to be audiorecorded and analysed by the qualita-
tive research team.
If the patient is willing to participate in the study, the 
RN will arrange to call the patient within 1–3 days to book 
a date for the screening appointment. During the tele-
phone call (also audiorecorded) the RN will answer any 
further patient questions and give the patient the oppor-
tunity to change their mind about study participation if 
they wish. If the patient confirms they would like to partic-
ipate, the RN will book the patient’s screening appoint-
ment at their local site.
At the screening and baseline appointments, informed 
consent will be obtained by the RN prior to the assess-
ments being performed. Throughout the recruitment 
process the RN will remind patients that they are under no 
obligation to enter the study and that they can withdraw 
at any time, without having to give a reason. No clinical 
trial procedures will be conducted prior to taking consent 
from the participant. Consent will not denote enrolment 
into trial. Figure 1 shows the flow of patients through the 
study and the assessments performed at each visit.
randomisation
Participants will be allocated to either of the two opera-
tions (see figure 1) using block randomisation stratified 
by centre to ensure that approximately equal numbers of 
patients are allocated to each treatment arm within each 
centre. The randomisation will be carried out using the 
web-based service from the company ‘Sealed Envelope’. 
Varying block sizes will be used and these will only be 
known to the statistician and Sealed Envelope.
data analysis plan
Quantitative data analysis
Descriptive analyses (means, SD and proportions) will 
be used to summarise the characteristics of the patients 
recruited to the study. A consort flow diagram will 
be produced to show the progress of the participants 
through the phases of the feasibility study and describe 
the follow-up at the various time-points. The study dataset 
will be analysed on an intention-to-treat basis. The primary 
and secondary outcomes will be analysed descriptively 
(using either proportions, or means, as appropriate) for 
each group. Differences between groups will be estimated 
and presented with 95% CIs. No formal comparisons will 
be made as the study is not powered for this. Stata V.14 
will be used for analysis.
Qualitative data analysis
Patient eligibility and recruitment pathway details will 
be mapped for each centre to include: the point at 
which patients receive information about the trial and 
encounter members of the clinical team and the timing 
and frequency of appointments. Logs of eligible and 
recruited patients will be assembled using simple flow 
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Figure 1 Flow diagram of the VOCALIST feasibility study. EAT-10, Eating Assessment Tool 10-items; ENT, ear, nose and throat; 
EQ-5D-5L; EuroQoL 5 Dimensions 5 Levels; LEMG, laryngeal electromyography; OperaVOX, On person Rapid Voice Examiner; 
VHI-10, Voice Handicap Index 10.
charts and counts to display numbers and percentages of 
patients at each stage of the eligibility and recruitment 
process. Audio recordings of the recruitment conver-
sations will be analysed using established techniques of 
applied conversation analysis23 to examine how patient 
consultations proceed and to identify any instances of 
interactional trouble which may impact on recruitment.
In-depth interviews will be conducted by the Quali-
tative Researcher with Trial staff (n=10 approximately, 
including members of the SMG, the CI and those most 
involved in the design and management of the trial 
and with clinical and recruitment staff across the three 
centres) and participants eligible for recruitment to the 
study (n=10 approximately, including those who accept 
and decline randomisation). Interviews will be anal-
ysed thematically, using a constant comparison meth-
odology until a point where theoretical saturation is 
accomplished.24
data management
Quantitative data will be collected at the trial sites using 
paper CRFs and entered centrally by the Trial Manager 
onto the online study database (provided by Sealed Enve-
lope). Any local data collection or data entry queries 
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raised by local sites will be brought to the attention of the 
central London team (TM). Identification logs, screening 
logs and enrolment logs will be kept at the trial site in a 
locked cabinet within a secured room.
Qualitative data will be recorded on encrypted audio 
recorders and transferred to the University of Bristol’s 
secure Research Data Storage Facility (RDSF). Interviews 
will be transcribed verbatim, with personal identifiers 
removed. Files will be stored on the University of Bristol’s 
secure RDSF.
At the end of the study, all study-related documents will 
be archived. The chief investigator will archive the study 
master file for 15 years in line with all relevant legal and 
statutory requirements. The principal investigator at each 
participating site will archive his/her respective site’s 
study documents for 15 years in line with all relevant legal 
and statutory requirements.
study monitoring
The study will be managed by the Study Management 
Group (SMG) consisting of the coinvestigators, site PIs 
and patient representative. They will meet every 2 months 
during the set up and duration of the study.
The study will be overseen by the Study Steering 
Committee (SSC), consisting of an independent chair, 
an independent clinician, an independent speech and 
language therapist and a patient representative. They will 
meet biannually with the CI and relevant members of the 
SMG.
Patient and public involvement
This research has been developed in response to patient 
demand for a trial which will deliver the answers they 
need to make an informed choice regarding their care. 
Patients and the public have been involved in confirming 
the need for the research, developing the trial design, 
choice of outcome measure and wording of patient 
documentation. Two patient representatives are active 
members of the SMG and SSC and have been provided 
with lay research training and support to ensure they 
understand their role in the research project, remain 
engaged as active partners and feel confident in their 
relationships with the research team. These patient 
representatives will continue to be involved throughout 
the feasibility study, including assisting with optimising 
recruitment and retention, interpreting the findings and 
disseminating the results to their formal and informal 
patient networks.
Ethics and dissemination
A favourable ethical approval was granted by the NRES—
Committee Bromley (reference number 11/LO/0583) 
prior to commencement of the study. Local approvals 
for each site have been sought prior to commencement 
of recruitment. All members of the research team and at 
each site will be trained in the aspects of good clinical 
practice appropriate to their role in the study.
To ensure the results from this feasibility study can be 
taken forward into a plan for a future large-scale RCT, 
there is a need to engage all those involved in voice 
health including ENT surgeons, speech therapists, voice 
and singing teachers, general practitioners and practice 
nurses. Therefore, results will be disseminated through 
the publication of articles in peer-reviewed medical jour-
nals targeted at health professionals involved in the care 
of patients with voice disorders and presented at national 
and international scientific meetings. Our findings and 
future trial plans will be discussed with relevant profes-
sional organisations including the British Laryngological 
Association (BLA) and Royal Colleges to ensure they are 
disseminated to their members through electronic news-
letters, websites and national meetings. Our Patient and 
Public Involvement representatives will assist in dissemi-
nating results in a suitable lay language to relevant jour-
nals and patient information sections of health-related 
websites, ensuring that patients and the public are both 
informed and engaged for the future RCT.
study status
At the time of manuscript submission, the feasibility study 
is open to recruitment.
conclusIon
Reports on short and long-term voice outcomes of patients 
who undergo thyroplasty are sparse and methodologi-
cally poor. The quality of the current literature regarding 
laryngeal reinnervation is also poor. For these reasons, 
the experienced multidisciplinary VOCALIST research 
team have designed this feasibility study to provide reli-
able information on how to conduct a future multicentre 
trial to determine the clinical and cost-effectiveness of 
laryngeal reinnervation versus thyroplasty for patients 
with UVFP. The combination of quantitative and qualita-
tive approaches and the support of the BLA and National 
Institute for Health Research Clinical Research Network 
will ensure that all aspects of feasibility are assessed, 
including patient recruitment strategies and appropriate 
outcome measures. The lessons learnt in this feasibility 
study will ensure the success of a future RCT (including 
whether training courses need to be developed to enable 
greater numbers of UK surgeons to perform laryngeal 
reinnervation surgery) ultimately enabling an evidence-
based pathway of care to be developed for patients with 
UVFP.
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